ClinicalTrials.gg
CompletedNCT03439943LixiParkUpdated Nov 28, 2025

Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease

A Phase 2 interventional study of Lixisenatide and placebo in Parkinson Disease, sponsored by University Hospital, Toulouse. Completed at 20 sites in France. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-11-28.

Sponsored by University Hospital, Toulouse · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 33 studies in Parkinson Disease by University Hospital, Toulouse — 7 open to participants now, 7 under way, 1 of them phase 3. Parkinson Disease · University Hospital, Toulouse.

Enrollment
3rd of 25
156 · median 38
Started
2018
with 1 other
Phase 2
5 of 33
1 open now
Registered
14th of 33
by date

Among the 33 studies in Parkinson Disease by University Hospital, Toulouse, this one is the 3rd largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2018, is one of 5 in phase 2, and was the 14th registered.

Parkinson Disease

4,581 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

7 of the 33 studies in Parkinson Disease by University Hospital, Toulouse are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 313 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Parkinson Disease by University Hospital, Toulouse, or all of them as a file.
02

Study summary

The main objective of the study is to evaluate the effect of lixisenatide (20 μg/d), versus placebo, administered as add-on therapy with the usual antiparkinsonian treatment, on the progression of motor disability in patients with early PD in order to assess its potential "disease-modifying" effect.

Read the detailed description

This study will be a French, multicenter parallel groups, 2-arm, randomized, placebo-controlled, double-blind, proof-of-concept (POC) phase II trial evaluating the effect of lixisenatide, in patients with early PD.

The treatment period will be followed by a wash-out period of 2 months.

JUSTIFICATION/CONTEXT Parkinson's disease (PD) is a common neurodegenerative disease. Currently available symptomatic treatments allow improving motor and to a lesser extent non-motor function in PD patients.

None of these treatments can slow down the underlining disease process and the relentless progression of motor and non-motor disability.

Several mechanisms including the aggregation of misfolded alphasynuclein, mitochondrial dysfunction, oxidative stress and neuroinflammation have been related to the pathogenesis of PD. Recent evidence further suggests the implication of cerebral insulin resistance in the neurodegenerative process, while glucagon-like peptide 1 receptor (GLP1-R) agonists that are approved for the treatment of type 2 diabetes have neuroprotective properties in animal models of PD (Aviles-Olmos et al., 2013a). Moreover, the results of a recent clinical pilot trial suggest that treatment with the GLP-1R agonist exenatide for 12 months improves motor function in patients with moderate PD . GLP1-R are widely expressed in the central nervous system and GLP1-R agonists such as liraglutide, lixisenatide and exenatide have measurable brain concentrations, which makes them suitable for treating brain disorders.

Lixisenatide is a well-tolerated GLP-1R agonist that can be administered once-daily (subcutaneous injection). It has demonstrated positive effects on learning and memory through an increase of hippocampal neurogenesis in preclinical models of obesity/diabetes. Furthermore, lixisenatide increases neurogenesis and decreases microglial activation in rodent models of Alzheimer's disease (APPswe/PS1ΔE9 mice and Aβ25-35 rats) (. At the same dose, lixisenatide showed higher effectiveness at activating brain GLP-1R than liraglutide and exenatide, and showed more effective neuroprotection in a variety of in-vitro models of neurodegeneration (WO2013/030409A1).

Thus, this randomized, double-blind, clinical trial now aim to evaluate the effects of lixisenatide, versus placebo, on both motor and non-motor PD symptoms in patients at an early stage of PD.

This study will involve centers of the French national Parkinson's disease and movement disorders research network (Ns-Park network).

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with PD according to UKPDSBB criteria (male or female).
  • Patient with a Hoehn and Yahr Stage \<3 in the ON condition.
  • Patients aged from 40 to 75 years old.
  • Early-stage PD patients: diagnosis of PD for less than 3 years, without dyskinesia and motor fluctuations.
  • Patients treated with an "optimized" stable dopaminergic medication regimen (dopamine agonist and/or L-dopa and/or MAOB inhibitor) for at least 1 month before baseline.
  • Patients expected to remain on stable doses of antiparkinsonian medications for at least the first 6 months of the study and preferably for the 12 months of follow-up.
  • Patients (or caregiver) able to self-administer lixisenatide injection.
  • Patients with health insurance.
  • Patients who signed the written form.

Exclusion criteria

Exclusion Criteria:

  • Patients suffering from other parkinsonian syndromes other than PD.
  • Patients expected not to be able to remain on stable doses of symptomatic antiparkinsonian medications for at least 6-month.
  • Patients with a \< 18.5
  • Patients suffering from type 1 or type 2 diabetes.
  • Malnutrition as assessed clinically by the investigator or any sub-investigator and by Mini Nutritional Assessment Short Form (MNA-SF) score \<12 (the judgement of the investigator prevails over questionnaire scores).
  • Weight change of more than 5 kg in body weight during the last 3 months prior to screening.
  • Known history of drug or alcohol abuse within 6 months prior to the time of screening.
  • Patients with hyperthyroidism or uncontrolled hypothyroidism. Note: Patients diagnosed with hypothyroidism need to be on a stable thyroid replacement therapy for at least 6 weeks.
  • Patients with severe depression according to DSM criteria.
  • Patients with cognitive impairment ( score \<26).
  • Severe gastrointestinal disease (e.g. gastroparesis).
  • Patients previously exposed to a GLP-1 agonist.
  • Patients with severely impaired renal function (estimated \<30ml/min).
  • Patients with a medical history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic active or C (assessed by medical history), primary biliary cirrhosis, or ongoing symptomatic gallbladder disease.
  • Patients with any abnormality.
  • Laboratory findings at the time of screening:

Amylase and/or lipase: >3 times the (ULN) laboratory range or AST: >3 times ULN Total : >1.5 times ULN (except in case of Gilbert's syndrome) Calcitonin: >20 pg/mL (5.9 pmol/L) : \<11 g/dL (male/female) and/or neutrophils \<1,500/mm3 and/or \<100,000/mm3 Triglyceride (TG): >600 mg/dL (6.78 mmol/L). History of unexplained pancreatitis, chronic pancreatitis or pancreatectomy.

  • Personal or immediate family history of medullary thyroid cancer or genetic conditions that predispose to medullary thyroid cancer (e.g. multiple endocrine neoplasia syndromes).
  • Hyperlipidemia.
  • Females who are pregnant, breast feeding or of child bearing age without effective .
  • Patients treated per os in the evening by drugs requiring a rapid action (at the discretion of the investigator).
  • Participants who lack the capacity to give .
  • Any medical or psychiatric condition which may compromise participation in the study or the safety, at the discretion of the investigator.
  • Known abnormality on CT or MRI brain imaging that is considered likely to compromise compliance with any aspect of the trial.
  • Prior intra-cerebral surgical intervention for PD.
  • Participant under legal guardianship or incapacitation.
  • Patients who are participating or have participated in another interventional clinical trial within 30 days prior to baseline.
  • Previous enrolment in the present trial.
  • Allergic reaction to the active substance or to any of the of lixisenatide
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
156 participants (actual)

Study arms

  • Experimental
    Lixisenatide

    Lixisenatide (10μg/d for 14 days and then 20μg/d): once daily subcutaneous

    Drug: Lixisenatide

  • Placebo comparator
    Placebo

    Placebo: once daily subcutaneous injection

    Drug: placebo

Interventions

  • Patients randomized in the Lixisenatide group will receive 10μg/day for 14 days and then 20μg/day administered by once-daily subcutaneous injections during 12 months. If patients are unable to tolerable the dose of 20μg/day, this dose can be reduced to 10μg/day

    Also known as: injection drug

  • Drugplacebo

    Patients randomized in the placebo group will receive the corresponding placebo administered subcutaneously (once daily subcutaneous injection).

    Also known as: placebo injection

06

What researchers measure

Primary outcomes

  1. Change from baseline to end-point (M12) in the MDS-UPDRS III motor (Movement Disorder Society-Unified Parkinson's disease rating scale)

    The main objective of the study is to evaluate the effect of lixisenatide (20 μg/d), versus placebo, administered as add-on therapy with the usual antiparkinsonian treatment, on the progression of motor disability in patients with early PD in order to assess its potential "disease-modifying" effect. The primary endpoint of this study is the change from baseline to end-point (M12) in the MDS-UPDRS III motor examination score, evaluated in the best ON condition in patients with early Parkinson's Disease.

    Time frame: 12 month

07

Study locations

20 sites
  • University Hospital of Amiens
    Amiens, France
  • University Hospital of Besancon
    Besançon, France
  • University Hospital of Bordeaux
    Bordeaux, France
  • University Hospital of Caen
    Caen, France
  • University Hospital of Clermont-Ferrand
    Clermont-Ferrand, France
  • Creteil- Henri Mondor Hospital
    Créteil, France
  • University Hospital of Lille
    Lille, France
  • University Hospital of Limoges
    Limoges, France
  • University Hospital of Lyon
    Lyon, France
  • University Hospital of Marseille
    Marseille, France
  • University Hospital of Montpellier
    Montpellier, France
  • University Hospital of Nancy
    Nancy, France
  • University Hospital of Nantes
    Nantes, France
  • University Hospital of Nice
    Nice, France
  • Pitié Salpêtrière Hospital
    Paris, France
  • University Hospital of Poitiers
    Poitiers, France
  • University Hospital of Rennes
    Rennes, France
  • University Hospital of Rouen
    Rouen, France
  • University Hospital of Strasbourg
    Strasbourg, France
  • CHU Toulouse
    Toulouse, 31000, France
08

References and documents

Publications

  • Meissner WG, Remy P, Giordana C, Maltete D, Derkinderen P, Houeto JL, Anheim M, Benatru I, Boraud T, Brefel-Courbon C, Carriere N, Catala H, Colin O, Corvol JC, Damier P, Dellapina E, Devos D, Drapier S, Fabbri M, Ferrier V, Foubert-Samier A, Frismand-Kryloff S, Georget A, Germain C, Grimaldi S, Hardy C, Hopes L, Krystkowiak P, Laurens B, Lefaucheur R, Mariani LL, Marques A, Marse C, Ory-Magne F, Rigalleau V, Salhi H, Saubion A, Stott SRW, Thalamas C, Thiriez C, Tir M, Wyse RK, Benard A, Rascol O; LIXIPARK Study Group. Trial of Lixisenatide in Early Parkinson's Disease. N Engl J Med. 2024 Apr 4;390(13):1176-1185. doi: 10.1056/NEJMoa2312323. PubMed 38598572 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Apr 2021, 34 months.

Of 105 non-industry phase 2 interventional studies under Parkinson Disease, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 34 months is close to that.

Counting every sponsor, half of 202 studies reached it within 28 months; a quarter within 16 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2018
First posted
Feb 20, 2018
StartActual
Jun 13, 2018
Primary completionActual
Apr 15, 2021
CompletionActual
Apr 15, 2021
Last update
Nov 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03439943
Collaborators
Cure Parkinson's, Réseau NS-Park, EUCLID Clinical Trial Platform, Sanofi
Responsible party
Sponsor
First posted
Feb 20, 2018
Start date
Jun 13, 2018
Primary completion
Apr 15, 2021
Completion
Apr 15, 2021
Last update
Nov 28, 2025

Study contacts

Olivier. RASCOL, MD, PHD
principal investigator · University Hospital, Toulouse

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lixisenatide

Start the discussion